Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 2/20 | 0.46 |
| ▸ | S1PR1 | P21453 | 5/20 | 0.41 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.40 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.40 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.39 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.38 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.37 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.36 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30602705 | 1.00 | KDM1A (0.46) | KDM1AS1PR1PDE3BPDE3ANOTUM | |
| SCHEMBL29426988 | 0.82 | KDM1A (0.42) | KDM1ANOTUMS1PR4HRH4OPRM1 | |
| SCHEMBL869450 | 0.82 | KDM1A (0.42) | KDM1ANOTUMS1PR4HRH4OPRM1 | |
| SCHEMBL10328468 | 0.79 | PTGDR2 (0.43) | KDM1AALDH1A1MAPK1 | |
| SCHEMBL30864218 | 0.78 | KDM1A (0.50) | KDM1ANOTUMS1PR4HRH4HCAR1 | |
| SCHEMBL6267032 | 0.78 | KDM1A (0.50) | KDM1ANOTUMS1PR4HRH4HCAR1 | |
| SCHEMBL5949403 | 0.76 | NOTUM (0.53) | S1PR1PDE3BPDE3ANOTUMTAS2R14 | |
| SCHEMBL31373429 | 0.76 | KDM1A (0.48) | KDM1APDE3BPDE3ANOTUMTAS2R14 | |
| SCHEMBL5574275 | 0.76 | GLA (0.54) | KDM1AS1PR4HRH4HCAR1 | |
| SCHEMBL84053 | 0.76 | SMN1; SMN2 (0.44) | S1PR1PDE3BPDE3ANOTUMTAS2R14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 208 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3692101-B1 | BRILLIANT BLUE (BBG) DYE DERIVATIVES AND STAINING COMPOSITIONS COMPRISING THE SAME FOR SELECTIVELY STAINING BIOLOGICAL SUBSTRATES | ALFA INSTR S R L (IT) | 2022-01-12 | — | — | EP | claimed |
| CN-107915570-B | Preparation method of 4-bromo-1-methyl-2- (trifluoromethyl) benzene | 金凯(辽宁)化工有限公司 | 2020-09-22 | — | — | CN | claimed |
| EP-3692101-A1 | BRILLIANT BLUE (BBG) DYE DERIVATIVES AND STAINING COMPOSITIONS COMPRISING THE SAME FOR SELECTIVELY STAINING BIOLOGICAL SUBSTRATES | Alfa Instruments S.r.l. (IT) | 2020-08-12 | — | — | EP | claimed |
| EP-3543319-A1 | METHOD OF MARKING HYDROCARBON LIQUIDS | Johnson Matthey Public Limited Company (GB) | 2019-09-25 | — | — | EP | claimed |
| WO-2019068935-A1 | BRILLIANT BLUE (BBG) DYE DERIVATIVES AND STAINING COMPOSITIONS COMPRISING THE SAME FOR SELECTIVELY STAINING BIOLOGICAL SUBSTRATES | ALFA INSTRUMENTS S.R.L. (IT) | 2019-04-11 | — | — | WO | claimed |
| US-20140120626-A1 | METHOD OF MARKING HYDROCARBON LIQUIDS | JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) | 2014-05-01 | — | — | US | claimed |
| EP-2707465-A1 | METHOD OF MARKING HYDROCARBON LIQUIDS | Johnson Matthey Public Limited Company (GB) | 2014-03-19 | — | — | EP | claimed |
| WO-2012153132-A1 | METHOD OF MARKING HYDROCARBON LIQUIDS | JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) | 2012-11-15 | — | — | WO | claimed |
| US-4436941-A | Process for the isomerization of alkylbenzotrifluorides | BAYER AKTIENGESELLSCHAFT (DE) | 1984-03-13 | — | — | US | claimed |
| US-20260125378-A2 | Heterocyclic Compounds | BEONE MEDICINES I GMBH (CH) | 2026-05-07 | — | — | US | disclosed |
| EP-4103557-B1 | MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2026-02-18 | — | — | EP | disclosed |
| US-20260022130-A1 | HETEROCYCLIC COMPOUNDS AS MONOACYLGLYCEROL LIPASE INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2026-01-22 | — | — | US | disclosed |
| US-12502378-B2 | Monoacylglycerol lipase modulators for use in autism spectrum disorders | JANSSEN PHARMACEUTICA NV (BE) | 2025-12-23 | — | — | US | disclosed |
| US-20250353846-A1 | Heterocyclic Compounds | BEONE MEDICINES I GMBH (CH) | 2025-11-20 | — | — | US | disclosed |
| WO-2005068463-A1 | DIAZA-SPIROPIPERIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2005-07-28 | — | — | WO | disclosed |
| US-20050154001-A1 | Diaza-spiropiperidine derivatives | HOFFMANN-LA ROCHE INC. | 2005-07-14 | — | — | US | disclosed |
| EP-0084648-B1 | PROCESS FOR THE ISOMERIZATION OF ALKYLBENZOTRIFLUORIDES | BAYER AG (DE) | 1984-11-07 | — | — | EP | disclosed |
| US-4436941-A | Process for the isomerization of alkylbenzotrifluorides | BAYER AKTIENGESELLSCHAFT (DE) | 1984-03-13 | — | — | US | disclosed |
| EP-0084648-A1 | Process for the isomerization of alkylbenzotrifluorides | BAYER AG (DE) | 1983-08-03 | — | — | EP | disclosed |
| US-4132737-A | ENZYME INHIBITORS | ELI LILLY AND COMPANY (US) | 1979-01-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260125378-A2 | Heterocyclic Compounds | NFATC1, CD4, MALT1 | KDM1A 2115/4885S1PR1 904/4885PDE3B 2713/4885 |
| US-20260022130-A1 | HETEROCYCLIC COMPOUNDS AS MONOACYLGLYCEROL LIPASE INHIBITORS | LIPC, LIPA, LPL | KDM1A 1310/4885S1PR1 977/4885PDE3B 1117/4885 |
| US-20250353846-A1 | Heterocyclic Compounds | NFATC1, CD4, ACIN1 | KDM1A 2061/4885S1PR1 2617/4885PDE3B 1880/4885 |
| US-20050154001-A1 | Diaza-spiropiperidine derivatives | HCN3, SCN3A, SLC6A3 | KDM1A 2461/4885S1PR1 972/4885PDE3B 293/4885 |
| US-12502378-B2 | Monoacylglycerol lipase modulators for use in autism spectrum disorders | LIPC, LPL, MGLL | KDM1A 350/4885S1PR1 807/4885PDE3B 320/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.